Safety of Osteoanabolic Therapy: A Decade of Experience

被引：103

作者：

Capriani, Cristiana ^{[1
]}

Irani, Dinaz ^{[1
]}

Bilezikian, John P. ^{[1
]}

机构：

[1] Columbia Univ, Coll Phys & Surg, Metab Bone Dis Unit, Div Endocrinol,Dept Med, New York, NY USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2012年 / 27卷 / 12期

关键词：

PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; LONG-TERM TREATMENT; IMPROVES TRABECULAR ARCHITECTURE; POSTMENOPAUSAL WOMEN; CANCELLOUS BONE; OSTEOSARCOMA INCIDENCE; REPLACEMENT THERAPY; VERTEBRAL FRACTURE; DOUBLE-BLIND;

D O I：

10.1002/jbmr.1800

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2419 / 2428

页数：10

共 92 条

[31] Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials [J].

Han, S-L. ;

Wan, S-L. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (02) :199-209

[32] Osteosarcoma and teriparatide? [J].

Harper, Kristine D. ;

Krege, John H. ;

Marcus, Robert ;

Mitlak, Bruce H. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (02) :334-334

[33] Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)] [J].

Harper, Richard P. ;

Fung, Eugene .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007, 65 (03) :573-580

[34] Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis [J].

Hodsman, AB ;

Hanley, DA ;

Ettinger, MP ;

Bolognese, MA ;

Fox, J ;

Metcalfe, AJ ;

Lindsay, R .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5212-5220

[35] Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use [J].

Hodsman, AB ;

Bauer, DC ;

Dempster, DW ;

Dian, L ;

Hanley, DA ;

Harris, ST ;

Kendler, DL ;

McClung, MR ;

Miller, PD ;

Olszynski, WP ;

Orwoll, E ;

Yuen, CK .

ENDOCRINE REVIEWS, 2005, 26 (05) :688-703

[36] BONE DENSITOMETRIC AND HISTOMORPHOMETRIC RESPONSES TO SEQUENTIAL HUMAN PARATHYROID-HORMONE (1-38) AND SALMON-CALCITONIN IN OSTEOPOROTIC PATIENTS [J].

HODSMAN, AB ;

STEER, BM ;

FRAHER, LJ ;

DROST, DJ .

BONE AND MINERAL, 1991, 14 (01) :67-83

[37] Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis [J].

Hodsman, AB ;

Kisiel, M ;

Adachi, JD ;

Fraher, LJ ;

Watson, PH .

BONE, 2000, 27 (02) :311-318

[38]

Hyldstrup L, 2001, BONE, V28, pS97

[39] Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis) [J].

Jerome, CP ;

Johnson, CS ;

Vafai, HT ;

Kaplan, KC ;

Bailey, J ;

Capwell, B ;

Fraser, F ;

Hansen, L ;

Ramsay, H ;

Shadoan, M ;

Lees, CJ ;

Thomsen, JS ;

Mosekilde, L .

BONE, 1999, 25 (03) :301-309

[40] Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis) [J].

Jerome, CP ;

Burr, DB ;

Van Bibber, T ;

Hock, JM ;

Brommage, R .

BONE, 2001, 28 (02) :150-159

← 1 2 3 4 5 6 7 8 9 10 →